跳轉至內容
Merck

[Clinical strategies for prevention of drug-induced urinary calculi].

Clinical calcium (2011-10-01)
Yasuo Kohjimoto, Yumiko Sasaki, Isao Hara
摘要

Drug-induced urinary calculi, although they account for only 1-2% of urinary calculi, deserve consideration because most of them are preventable. In the drug-containing calculi resulting from the crystallization of a certain drug and its metabolites in the urine, stone analysis can identify the responsible drug. While, in the drug-induced metabolic calculi caused by interference with calcium, oxalate and purine metabolism, careful clinical inquiry is necessary to reveal involvement of a certain drug in stone formation. Better awareness of the possible drugs with lithogenic potential and close surveillance of patients on long-term treatment with these drugs are necessary. Especially, in patients with a history of urolithiaisis, prescription of lithogenic drugs deserve careful consideration.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
弗洛里西®, 100-200 mesh
Supelco
Florisil® 色谱吸附剂, 60-100 mesh
Supelco
弗洛里西®, PR grade, 60-100 mesh, coarse powder
Supelco
弗洛里西®, 100-200 mesh, fine powder
Sigma-Aldrich
氨苯蝶啶, ≥99%
Supelco
Florisil®, for the determination of hydrocarbon acc. to ISO 9377-2
Supelco
弗洛里西®, <200 mesh, fine powder
Supelco
过弗罗里 ® PR, PR grade (analysis acc. to FDA)
Supelco
色谱用 Florisil ® 吸附剂, 30-60 mesh
Supelco
苯溴马隆, analytical standard
苯溴马隆, European Pharmacopoeia (EP) Reference Standard